Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03QAS
|
|||
| Former ID |
DIB000272
|
|||
| Drug Name |
E-758
|
|||
| Synonyms |
E-759; E-761; Lycobetaine analogs (cancer); Lycobetaine analogs (cancer), Oncotest; Topoisomerase inhibitors (cancer), Oncotest
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
| Company |
Oncotest GmbH
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [1] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Lycobetaine acts as a selective topoisomerase IIbeta poison and inhibits the growth of human tumour cells. Br J Cancer. 2001 November; 85(10): 1585-1591. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.